Breathing-linked pacemaker pacing after bypass surgery for heart failure with reduced ejection fraction
Official title: Respiratory Sinus Arrhythmia Pacing Post-CABG Surgery in Patients With HFrEF
Run by Ceryx Medical Ltd · NCT06384963 · Data updated 2026-11-12
This will test a pacemaker setting that restores the heart's natural breathing-linked rate in people with reduced ejection fraction after bypass surgery to see if it is safe and improves heart function.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 22 Years and up |
| Sex | All |
| Enrollment | 54 (estimated) |
| Sponsor | Ceryx Medical Ltd Industry-sponsored |
| Locations | 3 sites (Adelaide, South Australia and 2 other locations) |
| Status | Recruiting |
| Started | September 2, 2024 |
| Main results expected | March 1, 2026 |
| Study ends | April 1, 2026 |
| Registry record updated | July 22, 2025 |
| Trial ID | NCT06384963 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 22 or older with HFrEF (left ventricular EF 20–40%), in sinus rhythm, scheduled for isolated on-pump CABG including the left anterior descending artery, and able to give informed consent are the intended participants.
✕Probably not a fit
Patients with atrial fibrillation or flutter, an existing pacemaker or defibrillator, emergency or off-pump CABG, intrinsic resting heart rate over 100 bpm, pregnancy, or inability to consent are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This first-in-human, multicentre, randomized controlled trial compares respiratory sinus arrhythmia (RSA)–modulated atrial pacing to standard monotonic atrial pacing in patients with HFrEF undergoing on-pump CABG. Participants receive the assigned pacing for up to 10 days while monitored closely in hospital, with baseline testing before surgery and a phone follow-up at one month. The primary outcome is safety measured by arrhythmia episodes, and secondary outcomes include measures of cardiac function, cardiac output, and apnoea episodes. The trial aims to see whether restoring breathing-linked heart rate variability improves short-term postoperative cardiac performance without increasing risk.
Why it matters
Potential benefit: If successful, RSA pacing could improve cardiac output and short-term recovery after CABG for people with HFrEF while maintaining typical pacemaker safety.
How similar studies have gone: This is a first-in-human test of RSA pacing: animal studies suggested improved cardiac function but human data are currently lacking.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (≥ 22 years) selected for isolated, on-pump coronary artery bypass graft (CABG) * Established diagnosis of heart failure with reduced ejection fraction (HFrEF). * Elective or urgent admission routes * Echocardiography assessment of left ventricular ejection fraction (EF) of 20%-40% (within 1 month of planned surgery) * Sinus rhythm * Any number of coronary vessels replaced. Must include left anterior descending artery. * Able to provide written informed consent Exclusion Criteria: * Requirement for concurrent valve replacement surgery. * Off-pump CABG. * Emergency CABG * History of paroxysmal or permanent atrial fibrillation or flutter * History of atrioventricular-node dependent tachycardia * Patients lacking capacity to consent * Patient testing positive for Covid-19 within 14 days of intended CABG (PCR or lateral flow test) * Intrinsic resting heart rate \> 100bpm * Pregnancy * Implanted pacemaker or defibrillator * Failure to obtain Uscom signals
Where it's running
-
Royal Adelaide Hospital
Adelaide, South Australia, Australia Recruiting -
Monash Health
Melbourne, Victoria, Australia Recruiting -
Waikato Hospital
Hamilton, New Zealand Recruiting
Study contacts
- Principal investigator: Martin Stiles, MB ChB — Waikato Hospital, Hamilton, New Zealand
- Study coordinator: Flora Yuen, BSc
- Email: flora.yuen@avaniaclinical.com
- Phone: +61 438 890 650
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Yoga-based cardiac rehabilitation for heart failure with reduced ejection fraction
This trial tests whether a yoga-based rehabilitation program can help people with heart failure and reduced ejection fraction compared with an educational program.
-
Lumacaftor to improve cerebral blood flow in heart failure with reduced ejection fraction
This study tests whether lumacaftor can improve brain blood flow and thinking abilities in adults with a certain type of heart failure.
-
Stepwise withdrawal of ARNI and SGLT2i in HF with normalized ejection fraction
This trial tests whether gradually stopping ARNI and SGLT2i is safe for people whose heart function has recovered after fixing a reversible heart‑disease cause.
-
Ring-style blood pressure bracelet test compared with 24-hour monitoring in people with HFrEF
A ring-type blood pressure device is being tested to see if its 24-hour readings match those from standard ambulatory monitoring in adults with heart failure and reduced ejection fraction.
-
Diet and exercise plan to help people with heart failure and preserved heart function.
This study tests whether a DASH-style, high-protein diet, resistance exercise, or both can help build muscle and improve fitness and quality of life in people with heart failure and reduced ejection fraction.
-
HFrEF polypill strategy in Sri Lanka
This study tests whether giving a heart failure polypill can reduce death from heart disease and hospitalizations in adults with HFrEF in Sri Lanka, compared with usual care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.